PARP Inhibitors Provide New Promise for Certain Metastatic Breast Cancers
SHARE

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated November 20th, 2019

PARP Inhibitors Provide New Promise for Certain Metastatic Breast Cancers

×

Medical Source:

Dr. Heather McArthur
Cedars-Sinai Medical Center

PARP inhibitors are a new form of targeted therapy that can stop cancer cells from repairing their damaged DNA, causing them to die. The FDA recently approved them for the treatment of BRCA-mutation related metastatic breast cancer. Those kinds of cancers are more likely to be triple negative breast cancer, which can be more aggressive. Recent data has shown that women who received PARP inhibitors did better overall than patients who received chemotherapy.

“This broadens our arsenal for the treatment of triple negative breast cancer beyond conventional chemotherapy,” says Dr. Heather McArthur, Medical Director of Breast Oncology at Cedars-Sinai Medical Center.


Learn more about SurvivorNet's rigorous medical review process.

Dr. Heather McArthur is Medical Director of Breast Oncology at Cedars-Sinai Medical Center in Los Angeles. Read More

Medical Source:

Dr. Heather McArthur
Cedars-Sinai Medical Center

PARP inhibitors are a new form of targeted therapy that can stop cancer cells from repairing their damaged DNA, causing them to die. The FDA recently approved them for the treatment of BRCA-mutation related metastatic breast cancer. Those kinds of cancers are more likely to be triple negative breast cancer, which can be more aggressive. Recent data has shown that women who received PARP inhibitors did better overall than patients who received chemotherapy.

“This broadens our arsenal for the treatment of triple negative breast cancer beyond conventional chemotherapy,” says Dr. Heather McArthur, Medical Director of Breast Oncology at Cedars-Sinai Medical Center.

Read More

Learn more about SurvivorNet's rigorous medical review process.

Dr. Heather McArthur is Medical Director of Breast Oncology at Cedars-Sinai Medical Center in Los Angeles. Read More

Treating Late-Stage Breast Cancer

This series explains what to expect when you are given a late-stage breast cancer diagnosis. The important thing to remember is that there are still many treatment options, and with every passing year, doctors are finding even more treatments to add to their tool kit.

NOW
PLAYING
Hopeful News for Breast Cancer: A New Drug Combination to Extend Survival Time
NOW
PLAYING
CD4/CD6 Inhibitors For Metastatic Breast Cancer -- What Are The Side Effects?
NOW
PLAYING
What Are CD4/CD6 Inhibitors? And How Can They Fight Advanced Breast Cancer?
NOW
PLAYING
The FDA Just Approved a Promising New Drug for Metastatic Breast Cancer
NOW
PLAYING
Why Are Black Women More Likely To Die From Breast Cancer? Ellen DeGeneres Fan Favorite Lisa Jarmon Dies Of Stage IV Breast Cancer
NOW
PLAYING
Living Better -- What is Palliative Care?

Later Stage Treatment: Understanding The Options

SEE MORE   
Later Stage

Overview of Treatment for Advanced Breast Cancer

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

Stage Four Breast Cancer

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

When Breast Cancer Spreads to the Bones

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

Metastatic Breast Cancer: You Are Not a Statistic

Later Stage Treatment: Understanding The Options

Later Stage Treatment: Hormone Receptor Positive Breast Cancer

SEE MORE   
Later Stage

What Are CD4/CD6 Inhibitors? And How Can They Fight Advanced Breast Cancer?

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

Treating Metastatic Hormone Receptor-Positive Breast Cancer

Dr. Erica Mayer
Dana-Farber Cancer Institute
Later Stage

Hormone Therapies for Breast Cancer: CDK 4/6 Inhibitors

Dr. Erica Mayer
Dana-Farber Cancer Institute
Later Stage

CDK4/6 Inhibitors for Breast Cancer Explained

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

CD4/CD6 Inhibitors For Metastatic Breast Cancer -- What Are The Side Effects?

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

Hormone Therapies for Breast Cancer: mTOR Inhibitors

Dr. Erica Mayer
Dana-Farber Cancer Institute
Later Stage

The FDA Just Approved a Promising New Drug for Metastatic Breast Cancer

Caroline Hopkins
SurvivorNet
Later Stage

New Breast Cancer Drug Combination Shows Promising Results

Caroline Hopkins
SurvivorNet

Later Stage Treatment: Hormone Receptor Positive Breast Cancer

Later Stage Treatment: Triple Negative Breast Cancer

SEE MORE   
Later Stage

Breast Cancer Breakthrough: Immunotherapy Shows Major Boost in Survival Rates

Later Stage

Chemo Plus Immunotherapy for Metastatic Triple-Negative Breast Cancer

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center
Later Stage

New Drug Extends Life in Most Aggressive Breast Cancer

Sonya Collins
Later Stage

What's Next for Breast Cancer and Immunotherapy?

Dr. Sylvia Adams
NYU Perlmutter Cancer Center
Later Stage

Immunotherapy and Triple Negative Breast Cancer

Dr. Heather McArthur
Cedars-Sinai Medical Center
Later Stage

PARP Inhibitors Provide New Promise for Certain Metastatic Breast Cancers

Dr. Heather McArthur
Cedars-Sinai Medical Center

Later Stage Treatment: Triple Negative Breast Cancer

Later Stage Treatment: Should I Consider Clinical Trials?

SEE MORE   
Treatment

Clinical Trials for Breast Cancer

Dr. Elizabeth Comen
Memorial Sloan Kettering Cancer Center

Why I'd Choose a Clinical Trial For Myself

Dr. Ben Neel
NYU Perlmutter Cancer Center
Treatment

When Should I Consider Clinical Trials?

Dr. Leena Gandhi

Dr. Alana Welm

Huntsman Cancer Institute
Later Stage

Clinical Trials and What Statistics Really Mean

Dr. Scott Strome
University of Maryland
Treatment

The Father of Immunotherapy Recommends Multiple Opinions

Dr. Steven Rosenberg
National Cancer Institute

Later Stage Treatment: Should I Consider Clinical Trials?

Continue The Journey

Explore: Later Stage Treatment

Related Articles

British Marine Runs Five Marathons in Five Days to Raise Money for Sister’s Metastatic Breast Cancer Treatment

Irish Singer Linda Nolan Battling Breast Cancer Alongside Her Sister, Anne Nolan: ‘The Chemo Sisters’

Radio Host Dan Bongino’s Cancer Story Gives Stage Four Patient Hope
Treatment

“A Second Opportunity at Life”– Maribel Ramos Is Thriving 5 Years After Experimental Immunotherapy for Triple-Negative Breast Cancer
Close

SN GUIDES

The First 60

Begin the breast cancer journey with confidence.

SIGN UP NOW

Thank you!

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.